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Abstract. Endometriosis is a gynaecological condition with 
an associated chronic inflammatory response. The ectopic 
growth of ‘lesions’, consisting of endometrial cells outside the 
uterine cavity, stimulates an inflammatory response initiating 
the activation of macrophages, and resulting in increased 
cytokine and growth factor concentrations in the peritoneal 
fluid (PF). Endometriosis‑associated inflammation is chronic 
and long lasting. In patients with endometriosis, the risk of 
developing ovarian cancer within 10 years, particularly of the 
endometrioid or clear cell subtype, is increased 2.5‑4 times. 
Endometriosis creates a peritoneal environment that exposes 
the affected endometriotic and the normal ovarian surface 
epithelial cells to agents that have been suggested to be 
involved in the pathogenesis of cancer. Concentrations of 
several cytokines and growth factors were increased in the 
PF of patients with endometriosis. The ovarian cancer marker, 
CA125, was one such growth factor; however, this remains 
to be confirmed. Human epididymis protein 4 (HE4) was 
detected at high concentrations in patients with ovarian cancer 
and was identified as the best biomarker for the detection of 
ovarian cancer. The present study determined the levels of 
HE4 and CA125 in the peritoneal fluid of 258 patients with 
and 100 control individuals without endometriosis attending 
the Department of Obstetrics and Gynaecology, University 
of Berne (Berne, Switzerland) between 2007 and 2014. The 
cases were subdivided into groups without hormonal treatment 
(n=107), or treated with combined oral contraceptives (n=45), 
continuous gestagens (n=56) or GnRH agonists (n=50). Both of 
these markers were significantly increased in the non‑treated 
endometriosis samples compared with the control group. 
Hormone treatment with either of the three agents mentioned 
resulted in the concentration of CA125 returning to the control 
levels and the concentration of HE4 decreasing to below the 
control levels. CA125, however not HE4, significantly differed 
between the proliferative and secretory cycle phases. Since 
HE4 is sensitive to hormonal treatment and robust towards 
menstrual cycle variation, HE4 is potentially superior to 
CA125 as an endometriosis marker and therefore has greater 
potential as a marker for the identification of women at risk of 
developing ovarian cancer.
Introduction
Endometriosis is an extremely prevalent gynaecological disorder 
defined by the presence and growth of endometrial tissue outside 
the uterine cavity. It occurs in 10‑20% of females of reproduc-
tive age worldwide (1) and often results in severe pelvic pain (2) 
and reduced fecundity (3). It is a benign disease; however, it 
expresses malignant features, including angiogenesis, abnormal 
apoptotic patterns, unrestrained cellular proliferation and in rare 
cases, invasion of distant organs (4,5). Sampson's postulation (6) 
of retrograde menstruation of viable endometrial cells, which 
implant and grow at ectopic sites is still the most widely accepted 
theory for the histogenesis of endometriosis (7). The attachment 
of single cells to a substrate, their invasion, proliferation and 
vascularisation are properties that occur in carcinogenesis, and 
are similar or identical to the implantation of the embryo in the 
endometrium and to endometriosis.
An association between endometriosis and ovarian cancer 
has been previously demonstrated (8,9). Due to a lack of effec-
tive early detection methods and minimal physical symptoms, 
epithelial ovarian cancer is commonly diagnosed at advanced 
stages, resulting in one of the highest mortality rates amongst 
all gynaecological malignancies (10). The use of oral contra-
ceptives was demonstrated to be beneficial on the incidence of 
ovarian cancer (11,12). A possible explanation for an increased 
rate of malignant transformation in the ovary is provided by 
the ‘incessant ovulation’ theory which, although suggested a 
number of years ago, is currently regaining importance. This 
theory suggests a negative impact of each ovulation (13) via 
the underlying inflammatory response associated with each 
occurrence (14). Pregnancy and the use of contraceptives 
suppressing ovulation would therefore reduce the risk of 
ovarian cancer (15,16). 
In the peritoneal fluid (PF) of patients with endometriosis, 
a number of cytokines, chemokines and growth factors have 
been demonstrated to be expressed at higher levels compared 
with females without the disease (17‑21). The same has been 
suggested for the expression levels of CA125, a coelomic 
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epithelial membrane glycoprotein antigen of unknown 
biological function, which is widely used as a serum marker 
for ovarian cancer and other types of tumour. Certain studies 
have suggested the importance of CA125 as a marker for endo-
metriosis (22,23) and other previous studies have confirmed 
this (24,25). Additionally, CA125 has been demonstrated 
to be produced in vitro by endometrial tissue in explant 
cultures (26). CA125 is an established serum marker for 
epithelial ovarian cancer (27,28). Serum CA125 has also been 
demonstrated to be increased in non‑malignant disorders (29). 
The correlation between serum and PF CA125 has been previ-
ously demonstrated (25). Human epididymis protein 4 (HE4), 
a small glycoprotein and protease inhibitor first identified 
in epididymal epithelium, has been identified as an ovarian 
cancer marker, particularly for the serous and endometrioid 
type (30), and is superior to CA125 (31) either on its own or 
in combination with CA125 as defined by a higher detection 
rate (32‑34). The increased specificity of HE4 over CA125 was 
previously confirmed in a large patient cohort with benign 
diseases (35). 
The current available information regarding HE4 in the 
context of endometriosis in the literature is scarce and pertains 
exclusively to its concentration in the circulation. Additionally, 
to the best of our knowledge, no information exists with 
regards to HE4 in the PF of patients with endometriosis. The 
present study aimed to investigate the two ovarian cancer 
markers, CA125 and HE4, in the PF of patients with endo-
metriosis, with or without treatment with oral contraceptives 
(combined or gestagen‑only) or with GnRH agonists, and 
control individuals.
Materials and methods
Patient information. A total of 358 women were involved in 
the present study. They underwent laparoscopic surgery in 
the Department of Obstetrics and Gynaecology, University of 
Berne (Berne, Switzerland) between July 2007 and July 2014 
for reasons of chronic abdominal or menstrual pain, or as a 
result of unexplained infertility. Information regarding the 
presence and staging, or absence of endometriosis, hormonal 
treatment administration, and/or menstrual cycle stage was 
obtained together with the biological samples, or retrieved 
post hoc from the medical records. All enrolled women 
provided informed, written consent. The study was approved 
by the ethics committee of the Canton of Berne (approval 
no. KEK14903).
Patient exclusion criteria. PF was quantitatively collected 
from the Pouch of Douglas and clarified by centrifugation at 
800 x g for 10 min. The supernatant was stored at ‑80˚C in 
aliquots after recording the total volume. The total protein 
content was determined using a micro-bicinchoninic assay 
(Quanti‑Pro® BCA, Sigma‑Aldrich, St. Louis, MO, USA) 
to ascertain absence of dilution with abdominal flushing 
medium under the procedure. The PF samples with a total 
protein content of <10 mg/ml were excluded from the present 
study. Other exclusion criteria were as follows: The presence 
of haemolysis in the PF, the diagnosis of malignancies or 
the use of hormonal therapy in the three months prior to the 
procedure. 
A total of 258 patients with endometriosis and 100 control 
individuals without endometriosis were included. The group 
of cases included patients who did not receive any hormonal 
treatment in the 3 months prior to laparoscopy (n=107). Of 
these patients, 67 were in the proliferative and 28 were in 
the secretory phase of the menstrual cycle (cycle stage was 
peri‑ovulatory or unknown in 12 cases). The remaining cases 
were divided into three groups: Treatment with combined 
oral contraceptives (n=45), continuous progesterone (n=56) or 
GnRH agonists (n=50), all for at least 3 months leading up to 
the day of surgery. The control group (without endometriosis, 
n=100) consisted of 67 women in the proliferative menstrual 
cycle stage and 33 in the secretory menstrual cycle stage. The 
demographic information and PF characteristics are shown in 
Table I.
ELISA. CA125 and HE4 were quantified manually in the PF 
samples using commercially available microplate ELISA kits. 
For CA125, the TM‑CA125 ELISA kit (cat. no. EIA‑5072; 
DRG Instruments, Marburg, Germany) was used, according to 
the manufacturer's instructions. Incubation temperature was 
maintained at 28˚C without agitation. The functional sensi-
tivity was 0.25 U/ml and the intra‑ and inter‑assay coefficients 
of variance at 30 U/ml were 5.8 and 10.6%, respectively. The 
PF samples were diluted 1:21 with phosphate‑buffered saline, 
containing 0.1% (w/v) bovine serum albumin (Sigma‑Aldrich, 
Buchs, Switzerland). For HE4, the EIA kit 404‑10 (Fujirebio 
AB, Göteborg, Sweden) was used, according to the manufac-
turer's instructions. Incubations were performed at 28˚C with 
an agitation speed of 300 rpm. The detection limit was 15 pM 
(functional sensitivity, <2.5 pM), and the coefficient of vari-
ance (intra‑assay) was 2.4%. The PF samples were diluted 1:26 
with the zero calibrator of the assay kit. 
Statistical analysis. The concentrations of CA125 and HE4 
were compared non‑parametrically between the different 
groups using Mann‑Whitney U test. Correlation analyses were 
performed using Spearman's rank correlation, following log 
transformation of the X (HE4) and Y (CA125) axes, using 
Graph‑Pad Prism® v.5.04 software (GraphPad Software, Inc., 
La Jolla, CA, USA). P<0.05 was considered to indicate a statis-
tically significant difference.
Results
Levels of CA125 and HE4 vary in different patient samples. 
The levels of CA125 and HE4 were below the above mentioned 
detection limits in 2/358 and 1/358 PF samples, respectively. 
In the non‑parametrical statistical analysis these values were 
included as 10 U/ml for CA125 and 100 pmol/l for HE4. 
All results for CA125 and HE4 in the different groups and 
sub‑groups are shown in Table II. Marked patient‑to‑patient 
variations for the two markers were detected over two (CA125 
in controls only, <2) to three orders of magnitude. This is 
shown for CA125 and HE4 in Fig. 1A and B, respectively. 
Levels of CA125 and HE4 are affected by hormone treat-
ment. The concentrations of the markers were demonstrated 
to be significantly increased in the group of non‑treated 
endometriosis cases compared with the controls without 
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any sign of the disease. The P‑values were calculated for 
CA125 and HE4, and were revealed to be 0.0185 and 0.0105, 
respectively (Mann‑Whitney U test). Within the endome-
triosis cases, exposure to combined oral contraceptives and 
continuous progesterone resulted in the PF levels of CA125 
returning to that of the control group (P=0.02). No effect 
on CA125 was observed following treatment with GnRH 
agonists. The levels of HE4 were markedly decreased in all 
three hormone‑treated groups compared with the non‑treated 
controls (P<0.0001), and were even lower compared with 
the levels observed in the control group (Table II). CA125 
significantly differed in concentration between the prolif-
erative and secretory cycle phases in the controls and 
non-hormone-treated cases of endometriosis; however, this 
was not the case for HE4 (Fig. 1).
Effect of assessing both markers. The product of both markers 
(HE4 x CA125) was also compared between the different 
groups. When the non‑treated endometriosis cases were 
compared with the control group, the increase in this product 
was more pronounced (P=0.0061) compared with the two 
markers individually (Table II). When comparing prolifera-
tive and secretory phases the results for the product came to 
lie between those for the individual markers and the differ-
ence was significant in the control but not in the untreated 
endometriosis group. Conversely, the hormone treated groups 
demonstrated markedly decreased values for the product 
(P<0.0001 for all three hormones).
The concentrations of the two markers were revealed to be 
correlated with each other in all five groups and subgroups. 
Spearman P‑values were between 0.0101 (gestagen treated 
Table I. Demographic data and PF characteristics.
Characteristic N Age (years) BMI (kg/m2) PF volume (ml) PF protein (mg/ml)
No endometriosis 100 34.3±8.0 24.4±4.0   9.7±8.0 34.47±10.63
  Proliferative phase   67 33.6±8.0 24.3±4.5   8.5±8.1 32.96±9.87
  Secretory phase    33 35.7±7.9 24.7±3.0 12.2±7.3 37.57±11.59
Endometriosis  258
  Not treated 107 34.5±5.8 23.7±4.0 10.1±8.1 34.18±10.29
    Proliferative phase   67 33.6±5.7 23.8±3.9   9.5±8.0 31.60±10.39
    Secretory phase   28 35.2±5.2 22.9±3.3 12.6±8.7 38.62±7.03
    Peri-ovulatory or unknown   12
  OC treated   45 28.7±5.1 22.3±4.4 7.2±5.9 33.19±8.00
  Gestagen only treated   56 31.5±5.9 22.6±3.3 6.9±6.5 38.46±8.25
  GnRHa treated   50 31.6±5.7 22.2±3.6 8.1±7.6 36.78±7.67
Data are expressed as the mean ± standard deviation. PF, peritoneal fluid; BMI, body mass index; OC, oral contraceptives; GnRHa, GnRH 
agonist.
Table II. Ovarian cancer marker concentrations in peritoneal fluid.
  CA‑125 (U/ml)  HE‑4 (pmol/l)  CA‑125xHE‑4
Characteristic N median (range) P‑value median (range) P‑value P‑value
No endometriosis 100 806 (131‑8798) 0.0185a  4731 (<100‑27543) 0.0105a 0.0061a
  Proliferative phase 67 1064 (139‑5625)  5371 (<100‑27543)
  Secretory phase 33 566 (131‑8798) 0.0020b 2731 (103‑24138) 0.1826b 0.0394b
Endometriosis 258
  Not treated 107 1114 (<10‑12229)  6667 (162‑68506)
    Proliferative phase 68 1416 (72‑12229)  6707 (162‑68506)
    Secretory phase 30 818 (<10‑8853) 0.0175b 6641 (567‑21918) 0.6555b 0.3969b
  OC treated 45 762 (<10‑2709) 0.0178c 1652 (138‑13274) <0.0001c <0.0001c
  Gestagen only treated 56 865 (128‑5602) 0.0233c 1306 (112‑22782) <0.0001c <0.0001c
  GnRHa treated 52 926 (85‑9734) 0.2419c 1546 (<100‑34123) <0.0001c <0.0001c
Data are expressed as the median and range. P‑values were calculated by Mann‑Whitney U test. aControls (no endometriosis, N=100), vs. 
non‑treated endometriosis (N=107); bSecretory, vs. proliferative cycle phase in the same group; cCalculated, vs. non‑treated endometriosis. OC, 
oral contraceptives; GnRHa, GnRH agonist.
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group; r=0.3411) and <0.0001 (controls; r=0.5816). The 
Spearman r‑values were not identified to be significantly 
different between the five populations. These findings are 
shown in Fig. 2, following logarithmic transformation. 
Discussion
The present study findings not only confirm increased PF 
concentrations of the ovarian cancer marker CA125 in patients 
with endometriosis (24,25), but also demonstrate for the first 
time, to the best of our knowledge, similarly increased levels of 
the novel marker HE4 in this compartment. The two markers 
are shown to be closely correlated (P<0.01; Fig. 2), which is 
consistent with the results of a previous study that measured 
the concentration of the two markers in the serum of patients 
with ovarian cancer (36). Therefore, it may not be necessary to 
determine each of these markers, however, this will depend on the 
question under investigation. For the monitoring of an existing 
or suspected ovarian malignant pathology, it was demonstrated 
that the combination of the two markers provided an improved 
result compared with a single marker (32,34). The findings 
of the present study confirm that the multiplication product 
(CA125 x HE4, in arbitrary units) provides an improved ability 
to discriminate between cases and controls (P=0.0061; Table II). 
No information exists in the literature regarding the levels of 
HE4 in the PF of patients with endometriosis; however, a small 
number of previous studies have identified HE4 in the serum. 
A previous case report associated increasing levels of CA125, 
and low and stable serum levels of HE4 with the disease (37) 
indirectly, suggesting unchanged HE4 levels in endometriosis. 
A previous study observed no differences in the serum levels 
of HE4 between patients with endometriosis and controls, 
Figure 1. Tukey box and whisker plot of (A) CA125 and (B) HE4 concentrations in the PF of No Endo women, patients with endometriosis without hormonal 
treatment, under treatment with COC, GEST or GnRHa for at least 3 months prior to PF collection. Number of women per group and statistical significance 
are stated in Table II. P, proliferative phase of the menstrual cycle; S, secretory phase; PF, peritoneal fluid; No Endo, endometriosis‑free; NT, non‑treated; COC, 
combined oral contraceptives; GEST, gestagen‑only; GnRHa, GnRH agonist.
Figure 2. Correlation between the concentrations of CA125 and HE4 in the peritoneal fluid of 342 women. The regression lines were calculated linearly 
following double logarithmic transformation. All correlations, determined by Spearman Rank analysis, were statistically significant (P<0.01). No Endo, 
endometriosis‑free; COC, combined oral contraceptives; GnRHa, GnRH agonist.
  B  A
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or between the proliferative and secretory menstrual cycle 
phases (38). The same result was obtained following different 
hormone treatments, however, in these groups, particularly 
for GnRHa, the number of patients assessed was significantly 
smaller compared with that of the present study. All these 
absences of variations were advocated as an advantage of the 
HE4 test compared with the CA125 in patients with suspected 
ovarian cancer. A previous study investigated a large patient 
cohort (>1,000 patients) with benign gynaecological diseases, 
including endometriosis, and revealed an increased specificity 
of HE4 over CA125 as a result of less frequently increased levels 
in these females, particularly in the pre‑menopausal group (35). 
The present findings in the PF are parallel with a previous 
study in the serum (38) regarding the cycle phases and the two 
markers, however, not for HE4 regarding the presence of endo-
metriosis. Another previous study compared the serum levels of 
these markers between ovarian cancer and different endometri-
otic pathologies, and demonstrated that measuring both markers 
in the same sample made it possible to distinguish between the 
two pathologies, since HE4 but not CA125, was shown to be 
increased in endometriotic pathology (36). The mentioned study 
has the advantage of including cancerous and endometriosis 
groups, however, hormone exposure or cycle variations were not 
investigated. Further studies observing serum and PF from the 
same females are required to determine whether the differences 
between the present results and the few reports in the literature 
regarding HE4 increases in endometriosis are a consequence 
of the different compartments assessed. If so, the serum test for 
HE4 will be robust towards (independent from) menstrual cycle 
parameters or endometriotic pathologies; however, care may 
be required to ensure that no hormonal medication was used, 
since HE4 reacts even more significantly to these treatments 
compared with CA125.
Notably, a significant difference in the CA125 levels was 
demonstrated between the proliferative and secretory cycle 
phases in the controls and cases (which have not been exposed 
to hormonal treatment in the 3 months prior to PF collection). 
This is not in agreement with a previous report (24) in which 
the sample numbers were lower (11‑22) and the assay was based 
on a different, older antibody, which may be less specific. Care 
is required and the cycle phase must be taken into account. 
The present study hypothesised that HE4 (which in this study, 
in contrast to CA125, failed to distinguish between the cycle 
phases), may be a more ‘robust’ marker individually when the 
cycle phase is unknown or the population is distributed over 
the entire menstrual cycle. However, CA125 and HE4 may 
exhibit better predictive ability alone when an exclusively 
proliferative or an exclusively secretory phase population is 
investigated, respectively (Table II). However, this requires 
further confirmation using larger groups of samples and 
patients.
Treatment of endometriosis may reduce the risk of 
developing ovarian cancer. Current treatments include the 
administration of contraceptives, combined‑sequential or 
continuous, which inhibit ovulation and therefore, an addi-
tional inflammatory episode on the surface of the ovary and 
possibly in surrounding tissues. The use of contraceptives has 
also been demonstrated to reduce ovarian cancer risk inde-
pendently of the presence of endometriosis (11). The present 
study demonstrates reduced levels of CA125 and significantly 
reduced levels of HE4. This suggests the usefulness of contra-
ceptives, including gestagens, when administered alone in the 
treatment of endometriosis and potentially in the context of 
ovarian cancer, since these two proteins are associated with 
this pathology. In the present study the patients with endome-
triosis were not sub‑grouped as a function of lesion location, 
however, our previous study observed that women were less 
likely to develop ovarian lesions compared with lesions in 
other locations (peritoneal or recto‑vaginal) following the 
use of oral contraceptives (39). This is particularly notable in 
the context of the ovarian cancer risk discussed in the present 
study. Gonadotropin releasing hormone agonists (GnRHa) 
induce a hypo‑estrogenic state and therefore can be used in 
the treatment of endometriosis as long as the patient does 
not wish to become pregnant; this is also the case with other 
hormonal medications. The increased incidence of ovarian 
cancer in patients with endometriosis provides a reason to 
identify endometriosis as soon as it occurs. It is difficult to 
suggest whether the sub‑population with an increased risk 
may indeed be specifically characterised by increased levels 
of the ovarian cancer markers, CA125 and possibly HE4, in 
the phase of pre‑malignancy. The present study, nevertheless, 
suggests that the treatment of endometriosis is required as a 
result of its potential to reduce the risk of ovarian cancer, as 
well as to reduce symptoms such as pain.
The present results confirm those of a previous study (40) 
demonstrating that GnRHa, administered for the reduction 
of pain (41), resulted in a significant reduction in peritoneal 
pro‑inflammatory cytokine and growth factor levels, there-
fore mediating a regression in the inflammatory activity in the 
peritoneal environment in patients with endometriosis (42). 
The present study shows that several pro‑inflammatory cyto-
kines and growth markers exhibit reduced PF concentrations 
following GnRHa treatment in patients with endometri-
osis (42). It also reveals that CA125 levels are not reduced 
following such treatment while those of HE4 are (P<0.0001). 
HE4, therefore, may be an ideal marker, superior to CA125, 
for the success of medical treatment of endometriosis, since 
it responds similarly to the different categories of hormones 
and, as mentioned previously, does not depend on the 
menstrual cycle phase in the group of non‑treated patients.
A drawback of the present study is the absence of data 
regarding the occurrence of ovarian cancer in the study popu-
lation. It is extremely difficult to gather samples from patients 
with ovarian cancer, together with the complete information 
regarding the presence or absence of past endometriosis. 
Additionally, such a project would likely further benefit from 
the analysis of serum samples obtained during the endome-
triosis and the cancer phases. This was not performed in the 
present study where an increased specificity by the restric-
tion to the peritoneal compartment was targeted.
In conclusion, the present study shows that the treatment 
of patients with endometriosis with sex steroids or GnRHa 
reduced the exposure of ovarian epithelial cells to an inflam-
matory environment. Whether this may later have a beneficial, 
negative effect on the risk of developing ovarian cancer 
remains to be elucidated. The response of the peritoneal 
environment to such treatment may be monitored by ovarian 
cancer markers, including CA125 and HE4, with the latter 
being slightly superior to the former since it does not react to 
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menstrual cycle variations and the reductions in PF concentra-
tions are more pronounced. Variance of the results within one 
group, however, is not better (smaller) for HE4 than for CA125. 
Long-term studies, including observation of serum levels, are 
required to gain further insight.
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